Stryker Corp. (SYK-N) Stock Predictions - Stockchase
WATCH LIST
61
Stryker Corp. (SYK-N)

ON STOCKCHASE SINCE Feb 2002

manufactures orthopedic equipment

biotechnology/pharmaceutical

Stryker Corp.

SYK-N

29 watching          
Join the Discussion

Stryker Corp. (SYK-N) SAVE Feb, 16, 2019, 5:26 am

186.83 1.29 (0.7%)

About Stryker Corp. (SYK-N)

Stryker Corporation is a Fortune 500 medical technologies firm based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and ... More at Wikipedia

What the experts are saying about SYK-N



  • All
  • Filtered
Signal Opinion Expert
HOLD
Stryker Corp.(SYK-N) 

February 15, 2019

Earnings in last quarter had 6-7% organic growth, 2-3 times better than the competition. Not cheap at 23x earnings. Has differentiated itself from the others in its industry. As long as dividends are growing at a hefty rate, no reason to sell.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Earnings in last quarter had 6-7% organic growth, 2-3 times better than the competition. Not cheap at 23x earnings. Has differentiated itself from the others in its industry. As long as dividends are growing at a hefty rate, no reason to sell.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Driscoll

President , Liberty Internationa...

Price Price
$187.400
Owned Owned
Unknown

BUY
Stryker Corp.(SYK-N) 

February 13, 2019

A great medical tech company making equipment for knee replacements and spines. SYK spends a lot of time training doctors to use their equipment, which is not interchangeable with other manufacturers, so those doctors will continue to use SKY equipment. Demographics as society ages help SYK. Well-run, and it hit new highs today. This is a great story. Will do well long-term.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
A great medical tech company making equipment for knee replacements and spines. SYK spends a lot of time training doctors to use their equipment, which is not interchangeable with other manufacturers, so those doctors will continue to use SKY equipment. Demographics as society ages help SYK. Well-run, and it hit new highs today. This is a great story. Will do well long-term.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Harris, CF

Portfolio , Avenue Investment Ma...

Price Price
$185.630
Owned Owned
Unknown

BUY
Stryker Corp.(SYK-N) 

February 6, 2019

They do knee and hip replacements. SYK are active in tuck-in acquisitions which is quite accretive. They trade at a decent valuation. A consistent stock performer.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
They do knee and hip replacements. SYK are active in tuck-in acquisitions which is quite accretive. They trade at a decent valuation. A consistent stock performer.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Gordon Reid

President, GoodReid Investment ...

Price Price
$180.700
Owned Owned
No

TOP PICK
Stryker Corp.(SYK-N) 

February 4, 2019

Has grown its dividend 12% compounded over 5 years. A great international growth story in medical devices. They continue to invest in new technology. They're gaining market share. They're using robots to speed up operations with fewer problems. (Analysts’ price target is $190.40)
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Has grown its dividend 12% compounded over 5 years. A great international growth story in medical devices. They continue to invest in new technology. They're gaining market share. They're using robots to speed up operations with fewer problems. (Analysts’ price target is $190.40)
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
John O'Connell,

Chairman a, Davis Rea...

Price Price
$176.290
Owned Owned
Yes

TOP PICK
Stryker Corp.(SYK-N) 

November 20, 2018

His focus on healthcare equipment. Demographically positive. They make artificial knees and hips, and have introduced robots. Has held in well in market uncertainty. Will be developing more and more technologies. Yield is 1.1%. (Analysts’ price target is $185.27)
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
His focus on healthcare equipment. Demographically positive. They make artificial knees and hips, and have introduced robots. Has held in well in market uncertainty. Will be developing more and more technologies. Yield is 1.1%. (Analysts’ price target is $185.27)
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Zachary Curry

Chief Oper, Davis-Rea Ltd....

Price Price
$165.950
Owned Owned
Yes

PAST TOP PICK
Stryker Corp.(SYK-N) 

October 12, 2018

(A Top Pick August 21/17, Up 20%) Hips and knees. Robotic surgery and 3D printers. His fear is that Stryker will buy Globus, and the subsidiary will overtake the parent.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(A Top Pick August 21/17, Up 20%) Hips and knees. Robotic surgery and 3D printers. His fear is that Stryker will buy Globus, and the subsidiary will overtake the parent.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Driscoll

President , Liberty Internationa...

Price Price
$171.040
Owned Owned
Yes

HOLD
Stryker Corp.(SYK-N) 

September 12, 2018

This is a great company, he says, with a well-established track record.  The price is getting to the point, where you are paying a premium at this level.  He would diversify into other holdings as well, ideally through an ETF such as IHI-N  

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

This is a great company, he says, with a well-established track record.  The price is getting to the point, where you are paying a premium at this level.  He would diversify into other holdings as well, ideally through an ETF such as IHI-N  

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Cameron Hurst

Chief Inve, Equium Capital Manag...

Price Price
$173.290
Owned Owned
No

COMMENT
Stryker Corp.(SYK-N) 

August 7, 2018

They make bespoke equipment. This can never be Amazon’d because the representative from Stryker works so closely with the doctor when they implant a new device into a patient. They are well-run, their robotics are leading edge. He likes the sector and this individual company but he would manage the idiosyncratic risk in this space by buying the IHI (US medical devices) ETF.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

They make bespoke equipment. This can never be Amazon’d because the representative from Stryker works so closely with the doctor when they implant a new device into a patient. They are well-run, their robotics are leading edge. He likes the sector and this individual company but he would manage the idiosyncratic risk in this space by buying the IHI (US medical devices) ETF.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Cameron Hurst

Chief Inve, Equium Capital Manag...

Price Price
$165.180
Owned Owned
No

TOP PICK
Stryker Corp.(SYK-N) 

August 7, 2018

Compared to the competition, Stryker has 8% organic growth due to hips and knees business. Robotics for knees and 3D printers for hips are giving them an edge. Dividend’s been rising 14-15% per year. The premier medical device company. Yield is 1.1%. (Analysts’ price target is $182.10)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Compared to the competition, Stryker has 8% organic growth due to hips and knees business. Robotics for knees and 3D printers for hips are giving them an edge. Dividend’s been rising 14-15% per year. The premier medical device company. Yield is 1.1%. (Analysts’ price target is $182.10)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Driscoll

President , Liberty Internationa...

Price Price
$165.180
Owned Owned
Yes

BUY
Stryker Corp.(SYK-N) 

July 5, 2018

They are growing on robotics. On knee and hip are going to be the dominant player. It is the new wave.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

They are growing on robotics. On knee and hip are going to be the dominant player. It is the new wave.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$171.330
Owned Owned
Yes

BUY
Stryker Corp.(SYK-N) 

June 20, 2018

He has been watching them since $100.  They benefit from an economic barrier to entry, because competitors will struggle to gain market share due to the complexity of the medical procedures used to implant the devices.  There is a rumour they may look to make a major acquisition.  For a 5-10 year horizon, this is a great core holding.  Yield %.  (Analysts’ price target is unkown)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

He has been watching them since $100.  They benefit from an economic barrier to entry, because competitors will struggle to gain market share due to the complexity of the medical procedures used to implant the devices.  There is a rumour they may look to make a major acquisition.  For a 5-10 year horizon, this is a great core holding.  Yield %.  (Analysts’ price target is unkown)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Jason Del Vicar

Portfolio , HollisWealth...

Price Price
$169.540
Owned Owned
No

BUY
Stryker Corp.(SYK-N) 

June 12, 2018

This is a terrific company and demographics for their artificial hips and knees are very positive. They are rumoured to be considering buying Boston Scientific. Because of the high rumoured price, Boston Scientific is up today, and Stryker is down. He thinks that this area is very investible because long-term growth is so good. People should have an investment in this area. The 10% drop in the stock price yesterday piqued his interest, at this price. Price at time of interview was $164.15.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

This is a terrific company and demographics for their artificial hips and knees are very positive. They are rumoured to be considering buying Boston Scientific. Because of the high rumoured price, Boston Scientific is up today, and Stryker is down. He thinks that this area is very investible because long-term growth is so good. People should have an investment in this area. The 10% drop in the stock price yesterday piqued his interest, at this price. Price at time of interview was $164.15.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Baskin

President, Baskin Wealth Manage...

Price Price
$162.540
Owned Owned
No

TOP PICK
Stryker Corp.(SYK-N) 

March 21, 2018

Orthopedic equipment is a key part of their business. The frontrunner and pioneer of robotics in surgery, and gaining market share. For medtech, Stryker is where to be. (Analysts' target of $173.67)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Orthopedic equipment is a key part of their business. The frontrunner and pioneer of robotics in surgery, and gaining market share. For medtech, Stryker is where to be. (Analysts' target of $173.67)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$164.730
Owned Owned
Yes

BUY
Stryker Corp.(SYK-N) 

March 21, 2018

Smith & Nephew or Stryker? Smith: Knows it only marginally. The options S&N were generation aren't attractive enough for him to buy. Stryker: Keep an eye on this. Their robotic surgery is cutting a strong profile in orthopedic surgeries. It's definitely becoming the market leader.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Smith & Nephew or Stryker? Smith: Knows it only marginally. The options S&N were generation aren't attractive enough for him to buy. Stryker: Keep an eye on this. Their robotic surgery is cutting a strong profile in orthopedic surgeries. It's definitely becoming the market leader.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$164.730
Owned Owned
Yes

PAST TOP PICK
Stryker Corp.(SYK-N) 

February 14, 2018

(A Top Pick Mar. 16/17, Up 20%) Like the healthcare equipment space. Aging demographics are positive. They're getting into robots in surgeries, which he views as positive. Expects it to grow in this area.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(A Top Pick Mar. 16/17, Up 20%) Like the healthcare equipment space. Aging demographics are positive. They're getting into robots in surgeries, which he views as positive. Expects it to grow in this area.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Zachary Curry

Chief Oper, Davis-Rea Ltd....

Price Price
$156.240
Owned Owned
Yes

Showing 1 to 15 of 61 entries
Successfully Saved Company
Successfully Saved Company
7+
JOIN THE DISCUSSION
7 comments in the last 7 days